Impact of Gonadotoxic Therapies on Fertility
Recruiting now
Conditions studied: Cancer, Fertility Issues, Fertility Preservation, Toxicity Due to Chemotherapy, Toxicity Due to Radiotherapy, Effects of Immunotherapy
In brief
The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer. The main questions it aims to answer are: * in females, if cancer therapies reduce the Anti-Müllerian hormone (AMH) concentration (ovarian reserve); * in males, if cancer therapies reduce sperm concentration (sperm quality).
Key facts
- Study ID
- NCT05885048
- Run by
- Michael von Wolff
- People needed
- 7000
- Starts
- 2023-12-01
- Expected to finish
- 2038-12-31
- Last updated by the study team
- 2026-07-30
Who can join
Age: 14 and older, up to 50. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with cancer or with benign reasons undergoing chemotherapy and/or radiotherapy of the pelvis (females) and the testicles (males) and/or immune therapy;
- Willing to participate;
- Austria: 14-50 years old (adolescents and adults), Germany: 18-50 years old, Switzerland: 14-50 years old (adolescents and adults);
- Serum hormone analysis before gonadotoxic therapy (females) or serum hormone analysis and sperm analysis before gonadotoxic therapy (males).
You may not qualify if…
- Missing consent;
- Language barrier.
Where it is running
- University Women's Hospital (Inselspital) — Bern, Switzerland (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.